- Date: April 03, 2017
Cemark, one of the projects chosen during the previous edition of the CaixaImpulse programme, has already begun the testing phase of its research.
Endometrial cancer is the fourth most common in women and it affects more than 280,000 people per year. The number of cases per year has gone up by 21% since 2008. This is the reason why the researchers at Vall d’Hebron Hospital have created a standard diagnosis based on the observation of malignant cells in an endometrial biopsy.
As Eva Colas—a member of the Biomedical Research Group in Gynaecology of the Vall d'Hebron Research Institute (VHIR)—explains, the problem is that sometimes, it is not possible to obtain enough cells for the test to be valid. This situation happens in 22% of cases and leads to additional invasive testing. This is why the team wants to make diagnosis possible without performing tedious and invasive rounds of testing.
The greatest problem lies in the diagnosis, as it is a very tedious process which many women have to go through. One of the symptoms that can warn patients and doctors is abnormal vaginal bleeding, although it is a very unspecific sign.
The CaixaImpulse programme has provided consultancy services and funding to the researchers of Cemark. And they have been able to diagnose this cancer using endometrial fluid by performing a simple test based on the presence of two proteins.
Cemark’s work does not end here, as it still has to go through clinical practice, the valuation process and final kit development. “We have to continue working with the same motivation and desire to innovate together with a great team, as we get closer to the finish line”, concludes Eva Colas.
More programme highlights
March 21, 2018
Adrià Maceira is the CEO of CreatSens Health, one of the seven spin-offs emerged from CaixaImpulse. CreatSens is working on developing a device to measure important biomarkers in nephrology and cardiology from home.
March 19, 2018
Thanks to increased collaboration with EIT Health, the CaixaImpulse 2018 call for proposals is open to projects from any of the regional branches in the European consortium.
March 13, 2018
Founded at the Bellvitge Biomedical Research Institute (IDIBELL), ADmit Therapeutics is aiming to develop a diagnostic test to detect Alzheimer's disease in its very early stages.